TGFB1 and Hepatic fibrosis: In contrast, AMPK pathway agonists can significantly reduce the expression levels of fibrosis marks such as a-SMA, TGF-β and collagen1 in both in vivo and in vitro researches, thus reducing the degree of liver fibrosis (82).